Can a targeted nerve block cut opioid use and boost blood flow after leg bypass?
NCT ID NCT01785693
First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time
Summary
This trial tests whether adding a double nerve block (femoral and sciatic) before general anesthesia can reduce pain and morphine use after femoropopliteal bypass surgery in people with peripheral arterial disease. The block, using levobupivacaine and clonidine, may also widen blood vessels in the leg, potentially improving blood flow. Participants are adults aged 18-80 scheduled for this surgery, and the study measures morphine consumption, pain scores, and other outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- levobupivacaine and clonidine (nerve block)
- What this could lead to
- If effective, this nerve block could reduce opioid use and improve blood flow after leg bypass surgery, potentially speeding recovery.
- What could go wrong
- The trial is small and early, and results may not apply to all patients. Nerve blocks carry risks like bleeding or nerve damage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERIPHERAL ARTERIAL OCCLUSIVE DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU Clermont-Ferrand
Clermont-Ferrand, 63003, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Balloon coated with drug could keep leg arteries open longer
- Leg artery study halted: did platelet screening help?
- New drug APAC aims to prevent blood clots in leg artery patients
- PAD patients may get a boost from a single dose of vumerity
- New balloon coated with drug aims to keep leg arteries open longer